1. Introduction {#sec1}
===============

Acute upper gastrointestinal bleeding (AUGIB) is a life-threatening and frequent complication in cirrhosis with its mortality approaching 5-20% \[[@B1]--[@B4]\]. About 70% of AUGIB episodes in cirrhosis are due to esophageal variceal rupture secondary to portal hypertension \[[@B5]\]. The primary goals of therapy of AUGIB in liver cirrhosis are initial control of bleeding and prevention of early rebleeding \[[@B1], [@B5], [@B6]\]. According to the current guidelines, the mainstay pharmacological management of AUGIB should be the use of vasoactive drugs (terlipressin and somatostatin or its analogues), which can reduce portal blood flow and portal pressure \[[@B6]--[@B8]\].

Traditionally, it has been considered that variceal rupture bleeding is potentially more dangerous in cirrhosis due to the underlying coagulation abnormalities \[[@B9], [@B10]\]. In clinical practice, though not recommended, treating physicians arbitrarily prescribe hemostatic drugs, which act on vasculature or coagulation cascade, as adjuvants for control of bleeding \[[@B11]\]. However, the therapeutic effect of hemostatic drugs on AUGIB remains uncertain. The results of a recent meta-analysis showed that antifibrinolytic agents were deleterious in patients with acute or chronic liver disease and AUGIB \[[@B12]\]. Herein, we conducted a retrospective study to investigate the effect of hemostatic drugs on AUGIB in patients with liver cirrhosis.

2. Methods {#sec2}
==========

The study was approved by the Medical Ethical Committee of the General Hospital of Northern Theater Command with an approval number \[number K (2019)32\] and was performed according to the Declaration of Helsinki.

2.1. Study Design {#sec2.1}
-----------------

In this retrospective study, a total of 1026 cirrhotic patients with AUGIB who were consecutively admitted to the General Hospital of Northern Theater Command from January 2010 to June 2014 were screened. The inclusion criteria were as follows: (1) a diagnosis of liver cirrhosis, and (2) a diagnosis of AUGIB presenting with hematemesis and/or melena at admission. The exclusion criteria were as follows: (1) no episodes of gastrointestinal bleeding within 5 days before admission, and (2) only positive occult blood test. Age, sex, source of gastrointestinal bleeding, cause of liver disease, and malignancy were not limited. Repeated admission was not excluded. Finally, 982 patients were included in our study.

The following data was extracted from our retrospective database: demographic data (i.e., age and gender), etiology of liver disease, presence of hematemesis and/or melena at admission, and laboratory tests (i.e., red blood cell, hemoglobin, white blood cell, platelet count, total bilirubin, direct bilirubin, albumin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, blood urea nitrogen, creatinine, potassium, sodium, prothrombin time, activated partial thromboplastin time, and international normalized ratio \[INR\]). The Child-Pugh score and model for end-stage liver disease (MELD) score were calculated. The use of red blood cell transfusion and antibiotics as well as the use of vasoactive drugs (i.e., somatostatin and/or octreotide) and proton pump inhibitors (PPIs) were recorded. The grade of esophageal varices was evaluated \[[@B13]\]. The use of endoscopic variceal therapy, Sengstaken-Blakemore tube, and splenectomy with or without devascularization were also recorded.

Hemostatic drugs employed in our study included drugs acting on vascular wall or platelet (i.e., norepinephrine, carbazochrome sodium sulfonate, and Yunnan Baiyao), antifibrinolytic drugs (i.e., ethylenediamine diacetoacetic), thrombin (i.e., lyophilizing thrombin powder), hemocoagulase (i.e., snake venom hemocoagulase), and procoagulant drugs (i.e., vitamin K). Modes of administration included intravenous, oral, and topical administration. The mechanisms and indications of various hemostatic drugs are shown in Supplementary Table [1](#supplementary-material-1){ref-type="supplementary-material"}.

According to the use of these hemostatic drugs during hospitalization, we divided the patients into hemostatic drugs and no hemostatic drug groups. The major outcomes included a 5-day rebleeding rate and in-hospital mortality. Five-day rebleeding was defined as the recurrence of hematemesis and fresh melena within 5 days after the initial bleeding episode was completely controlled \[[@B3]\].

2.2. Statistical Analyses {#sec2.2}
-------------------------

Continuous variables were expressed as mean ± standard deviation and median (range). Categorical variables were expressed as frequency (percentage). Nonparametric Mann-Whitney *U* test was used for continuous variables, and chi-square test was used for categorical variables to compare the differences between hemostatic drugs and no hemostatic drug groups. A 1 : 1 propensity score matching (PSM) analysis was used. Matching factors included age, gender, etiology of liver diseases, which mainly include hepatitis B, hepatitis C, alcohol abuse, drug abuse, and autoimmunity, Child-Pugh score, MELD score, hematemesis, red blood cell transfusion, vasoactive drugs, antibiotics, PPIs, and endoscopic variceal therapy. After exclusion of patients with malignancy and those who underwent surgery, subgroup analyses were conducted in patients with Child-Pugh class B and C, MELD score \> 15 \[[@B14]\], and use of endoscopic variceal therapy and antibiotics. All statistical analyses were performed with IBM SPSS software version 20.0 (IBM Corp, Armonk, NY, USA) and Stata/SE 12.0 (Stata Corp, College Station, TX, USA) software. A histogram demonstrating the frequency of various hemostatic drugs used during the study period was drawn by the Excel version 10.0 (Microsoft Corp, Redmond Washington, USA).

3. Results {#sec3}
==========

3.1. Overall Analyses {#sec3.1}
---------------------

A total of 982 patients with cirrhosis and AUGIB were included in our study. Baseline characteristics of patients at admission were shown in [Table 1](#tab1){ref-type="table"}. The median age was 56.01 years (range: 6.28-95.13 years), and most patients were male (*n* = 688, 70.1%). Hepatitis B virus (*n* = 399, 40.6%) was the most common etiology of cirrhosis. One hundred and eighty-nine patients (19.2%) had malignancy, including 160 patients with liver cancer and 29 patients with extrahepatic cancer (i.e., lung cancer, breast cancer, gastric cancer, and rectal cancer). Most patients were in Child-Pugh class B (476/982, 52.80%). The median MELD score was 6.60 (range: -7.52-40.95). Endoscopy was performed in 702 patients. Detailed information regarding the grade of esophageal varices on endoscopy was clearly available in 563 patients. Hemostatic drugs group had a higher proportion of hematemesis at admission, lower levels of red blood cell, platelet count, albumin, and alkaline phosphatase, and higher levels of blood urea nitrogen, potassium, prothrombin time, and INR than no hemostatic drug group.

Blood transfusion was given in 640 (65.20%) patients, of whom 611 (62.20%) received red blood cell transfusion with a median of 4 units (range: 1.00-33.00). Somatostatin and/or octreotide were given in 892 (90.80%) patients. PPIs were given in 967 (98.50%) patients. Antibiotics were given in 468 (47.70%) patients. Endoscopic variceal therapy was performed in 574 (58.50%) patients. Sengstaken-Blakemore tube placement was given in 20 (1.90%) patients. Splenectomy with and without devascularization was performed in 9 (0.9%) patients. Hemostatic drugs group was more likely to receive blood transfusion, red blood cell transfusion, somatostatin and/or octreotide, and PPIs than no hemostatic drug group.

Among the hemostatic drugs, ethylenediamine diacetoacetic, white-browed snake venom hemocoagulase, and lyophilizing thrombin powder were common hemostatic drugs with a high utilization rate of up to 60%-70%. By contrast, carbazochrome sodium sulfonate, vitamin K, and snake venom hemocoagulase were uncommon hemostatic drugs with a relatively low utilization rate of about 10%. There was a trend in a lower utilization rate of norepinephrine, white-browed snake venom hemocoagulase, and lyophilizing thrombin powder over time. By contrast, there was a trend in a higher utilization rate of carbazochrome sodium sulfonate and snake venom hemocoagulase over time ([Figure 1](#fig1){ref-type="fig"}).

The 5-day rebleeding rate was 16.6% (*n* = 163), and in-hospital mortality was 6.8% (*n* = 67). Hemostatic drugs group had a significantly higher 5-day rebleeding rate than no hemostatic drug group (18.10% versus 5.40%, *P* = 0.001). In-hospital mortality was not significantly different between the two groups (7.10% versus 4.50%, *P* = 0.293). The causes of death included uncontrolled bleeding (*n* = 40), uncontrolled bleeding with hepatic encephalopathy (*n* = 5), end-stage liver disease (*n* = 20), and advanced hepatocellular carcinoma (*n* = 2).

3.2. PSM Analyses {#sec3.2}
-----------------

### 3.2.1. PSM Analyses of Any Hemostatic Drug {#sec3.2.1}

A total of 172 patients were included in PSM analyses. In the hemostatic drugs group (*n* = 86), most patients (*n* = 74) started using hemostatic drugs from the day at admission until the bleeding stopped or death, and average duration of hemostatic drugs was 6.99 days (range: 1-41 days); rebleeding occurred in 13 patients during hospitalization, all of which developed after the use of hemostatic drugs. Compared with no hemostatic drug group, hemostatic drugs group had a significantly higher incidence of 5-day rebleeding (15.10% versus 5.80%, *P* = 0.046). In-hospital mortality was statistically similar between the two groups (7.00% versus 3.50%, *P* = 0.304) ([Table 2](#tab2){ref-type="table"}).

### 3.2.2. PSM Analyses of Ethylenediamine Diacetoacetic {#sec3.2.2}

A total of 160 patients were included in PSM analyses. In the ethylenediamine diacetoacetic group (*n* = 80), rebleeding occurred in 10 patients during hospitalization, all of which developed after the use of ethylenediamine diacetoacetic. There was no significant difference in the incidence of 5-day rebleeding (13.30% versus 5.30%, *P* = 0.092) or in-hospital mortality (5.30% versus 4.00%, *P* = 0.699) between the two groups (Supplementary Table [2](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.3. PSM Analyses of Lyophilizing Thrombin Powder {#sec3.2.3}

A total of 140 patients were included in PSM analyses. In the lyophilizing thrombin powder group (*n* = 70), rebleeding occurred in 10 patients during hospitalization, all of which developed after the use of lyophilizing thrombin powder. There was no significant difference in the incidence of 5-day rebleeding (14.30% versus 5.70%, *P* = 0.091) or in-hospital mortality (2.90% versus 2.90%, *P* = 1.000) between the two groups (Supplementary Table [3](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.4. PSM Analyses of White-Browed Snake Venom Hemocoagulase {#sec3.2.4}

A total of 128 patients were included in PSM analyses. In the white-browed snake venom hemocoagulase group (*n* = 64), rebleeding occurred in 10 patients during hospitalization, all of which developed after the use of white-browed snake venom hemocoagulase. There was no significant difference in the incidence of 5-day rebleeding (12.50% versus 4.70%, *P* = 0.115) or in-hospital mortality (3.10% versus 3.10%, *P* = 1.000) between the two groups (Supplementary Table [4](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.5. PSM Analyses of Snake Venom Hemocoagulase {#sec3.2.5}

A total of 62 patients were included in PSM analyses. In the snake venom hemocoagulase group (*n* = 31), rebleeding occurred in 6 patients during hospitalization, all of which developed after the use of snake venom hemocoagulase. There was no significant difference in the incidence of 5-day rebleeding (19.40% versus 9.70%, *P* = 0.279) or in-hospital mortality (9.70% versus 3.20%, *P* = 0.301) between the two groups (Supplementary Table [5](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.6. PSM Analyses of Yunnan Baiyao {#sec3.2.6}

A total of 98 patients were included in PSM analyses. In the Yunnan Baiyao group (*n* = 49), rebleeding occurred in 13 patients during hospitalization, all of which developed after the use of Yunnan Baiyao. The incidence of 5-day rebleeding was significantly higher in the Yunnan Baiyao group (26.50% versus 4.10%, *P* = 0.002). There was no significant difference in the in-hospital mortality (12.20% versus 4.10%, *P* = 0.140) between the two groups (Supplementary Table [6](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.7. PSM Analyses of Norepinephrine {#sec3.2.7}

A total of 96 patients were included in PSM analyses. In the norepinephrine group (*n* = 48), rebleeding occurred in 10 patients (6 patients were treated with norepinephrine during the endoscopic variceal therapy procedure and 4 patients were treated with norepinephrine orally) during hospitalization, all of which developed after the use of norepinephrine. The incidence of 5-day rebleeding was significantly higher in the norepinephrine group (20.80% versus 6.20%, *P* = 0.037). In-hospital mortality was significantly lower in the norepinephrine group (0.00% versus 8.30%, *P* = 0.041) (Supplementary Table [7](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.8. PSM Analyses of Carbazochrome Sodium Sulfonate {#sec3.2.8}

A total of 62 patients were included in PSM analyses. In the carbazochrome sodium sulfonate group (*n* = 31), rebleeding occurred in 3 patients during hospitalization, all of which developed after the use of carbazochrome sodium sulfonate. There was no significant difference in the incidence of 5-day rebleeding (9.70% versus 3.20%, *P* = 0.301) or in-hospital mortality (6.50% versus 0.00%, *P* = 0.151) between the two groups (Supplementary Table [8](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.9. PSM Analyses of Vitamin K {#sec3.2.9}

A total of 64 patients were included in PSM analyses. In the vitamin K group (*n* = 32), rebleeding occurred in 10 patients during hospitalization, all of which developed after the use of vitamin K. The incidence of 5-day rebleeding was significantly higher in the vitamin K group (31.20% versus 6.20%, *P* = 0.010). There was no significant difference in the in-hospital mortality (15.60% versus 3.10%, *P* = 0.086) between the two groups (Supplementary Table [9](#supplementary-material-1){ref-type="supplementary-material"}).

3.3. Subgroup Analyses {#sec3.3}
----------------------

### 3.3.1. Subgroup Analyses of Patients with Child-Pugh Class B and C after Excluding Patients with Malignancy and Those Undergoing Surgery {#sec3.3.1}

After excluding patients with malignancy and those undergoing surgery, 523 patients had Child-Pugh class B and C. Hemostatic drugs group had a significantly higher incidence of 5-day rebleeding (18.10% versus 1.90%, *P* = 0.003), but there was no significant difference in the in-hospital mortality (7.40% versus 3.80%, *P* = 0.323) between the two groups.

### 3.3.2. Subgroup Analyses of Patients with MELD Score \> 15 after Excluding Patients with Malignancy and Those Undergoing Surgery {#sec3.3.2}

After excluding patients with malignancy and those undergoing surgery, 79 patients had a MELD score \> 15. Hemostatic drugs group had a significantly higher incidence of 5-day rebleeding (15.90% versus 4.30%, *P* = 0.003), but there was no significant difference in the in-hospital mortality (6.10% versus 3.30%, *P* = 0.278) between the two groups.

### 3.3.3. Subgroup Analyses of Patients Having Esophageal Varices on Endoscopy after Excluding Patients with Malignancy and Those Undergoing Surgery {#sec3.3.3}

After excluding patients with malignancy and those undergoing surgery, 471 patients had esophageal varices on endoscopy. There was no significant difference in the incidence of 5-day rebleeding (14.90% versus 8.30%, *P* = 0.218) or in-hospital mortality (3.50% versus 2.10%, *P* = 0.596) between the two groups.

### 3.3.4. Subgroup Analyses of Patients Receiving Endoscopic Variceal Therapy and Antibiotics after Excluding Patients with Malignancy and Those Undergoing Surgery {#sec3.3.4}

After excluding patients with malignancy and those undergoing surgery, 243 patients received both endoscopic variceal therapy and antibiotics. There was no significant difference in the incidence of 5-day rebleeding (18.90% versus 9.50%, *P* = 0.285) or in-hospital mortality (4.50% versus 0.00%, *P* = 0.321) between the two groups.

### 3.3.5. Subgroup Analyses of Patients with Liver Cancer {#sec3.3.5}

There were 160 patients with liver cancer. There was no significant difference in the incidence of 5-day rebleeding (26.10% versus 11.10%, *P* = 0.164) or in-hospital mortality (12.00% versus 11.10%, *P* = 0.915) between the two groups.

4. Discussion {#sec4}
=============

Hemostatic drugs have never been recommended by major practice guidelines and consensus for the management of AUGIB in liver cirrhosis \[[@B1]\]. This is primarily because previous studies did not find any benefit of hemostatic drugs for AUGIB \[[@B15]--[@B20]\], which is consistent with our findings. Notably, our overall, PSM, and subgroup analyses suggested that neither 5-day rebleeding rate nor in-hospital mortality was improved by the use of hemostatic drugs. This finding can be explained by the fact that AUGIB in cirrhosis is mainly caused by hemodynamic alterations of portal hypertension, but not coagulation disorder \[[@B21]--[@B23]\]. A well-known effect of vasoactive drugs is the visceral vasoconstriction, thus decreasing the portal pressure, so these drugs are the first-line choice of therapy for acute variceal bleeding \[[@B23]\]. By comparison, hemostatic drugs cannot act on portal pressure reduction.

Our study specifically analyzed the effect of different hemostatic drugs in patients with cirrhosis and AUGIB. The findings from PSM analyses performed according to the type of hemostatic drugs were similar to those from overall analysis ([Figure 2](#fig2){ref-type="fig"}).

Tranexamic acid is one of the most widely employed antifibrinolytic drugs \[[@B24]\]. A meta-analysis showed that the use of tranexamic acid might not reduce the mortality of AUGIB \[[@B15]\]. Tranexamic acid was administered to few patients in our study, but the majority of our patients received ethylenediamine diacetoacetic which has the same mechanism as tranexamic acid. Therefore, the findings of the previous meta-analysis might be comparable to our finding that ethylenediamine diacetoacetic did not improve the in-hospital outcome of cirrhosis with AUGIB.

The *ε*-aminocaproic acid is another antifibrinolytic drug. Gunawa and Runyon reported a potential benefit of *ε*-aminocaproic acid for hyperfibrinolysis, defined as abnormal euglobulin lysis time \< 120 min, in liver cirrhosis \[[@B16]\]. Among the 37 cirrhotic patients with hyperfibrinolysis who developed bleeding episodes and received *ε*-aminocaproic acid, the hemostatic successful rate was 92% (34/37). However, a control group without *ε*-aminocaproic acid was lacking and the findings might be inconclusive. By comparison, euglobulin lysis time was not regularly measured in our study, and the use of ethylenediamine diacetoacetic in our patients did not depend on the fibrinolysis status. Therefore, our study could not evaluate the benefits of ethylenediamine diacetoacetic in patients with hyperfibrinolysis.

Thrombin can directly affect the conversion from fibrinogen to fibrin clots and acts on the coagulation cascade \[[@B25]\]. A previous study demonstrated that endoscopic injection of human thrombin was effective for gastric variceal bleeding \[[@B26]\]. Additionally, an Indian prospective study including 20 patients with gastric variceal bleeding showed that endoscopic injection of human thrombin was effective and the hemostatic successful rate was 100% \[[@B18]\]. However, in the two studies, endoscopic injection was the only mode of administration, and only gastric and ectopic varices were treated. By comparison, our patients received oral or local spray of lyophilizing thrombin powder, and a majority of our patients had esophageal varices.

Hemocoagulase, which is extracted from the venom of a snake, such as *Brothrops atrox* and *Agkistrodon blomhoffii ussurensis*, has a thrombin-like effect \[[@B27]\]. Recently, a randomized controlled trial demonstrated that the topical spray of hemocoagulase might not significantly increase the rate of hemostatic success as compared with traditional 8% norepinephrine (100% versus 94.0%, *P* = 0.060) \[[@B17]\]. By comparison, in our study, no hemostatic drug was employed as the control group, and intravenous infusion of hemocoagulase was the only mode of administration. Notably, compared with local spray, intravenous infusion can cause hypofibrinogenemia, which may aggravate bleeding. Indeed, this phenomenon has been observed in several case reports \[[@B28]--[@B30]\].

Recombinant factor VIIa (rFVIIa) is not sufficiently supported by the current evidence for the management of acute variceal bleeding \[[@B6]\]. Two randomized controlled trials assessed the efficacy of rFVIIa for acute variceal bleeding in patients with cirrhosis \[[@B19], [@B31]\]. The first study assessed 245 cirrhotic patients with AUGIB by assessing a composite endpoint, which consisted of failure to control bleeding within 24 hours, failure to prevent rebleeding between 24 hours and day 5, or death within 5 days. Compared with placebo, rFVIIa significantly improved the composite endpoint (8% versus 23%, *P* = 0.03) in the subgroup analysis of Child-Pugh B class and C patients with variceal bleeding, despite the overall analysis found that the endpoint was not significantly different between rFVIIa and placebo groups (14% versus 16%, *P* = 0.72). Then, the investigators further selected a total of 256 cirrhotic patients with Child-Pugh class B and C and variceal bleeding in a second study to evaluate the same endpoint. Compared with placebo, rFVIIa did not add any significant benefit (23% versus 20%, OR = 0.80, *P* = 0.37) and had a lower rate of the composite endpoint (13%). Our meta-analysis of the two trials suggested that the difference in the endpoint was not significant between placebo and rFVIIa groups. Therefore, the effect of rFVIIa in cirrhotic patients with AUGIB remains controversial \[[@B32]\].

Vitamin K participates into the formation of coagulation factors II, VII, IX, and X in the liver and is usually used as a supplementary intervention \[[@B33]\]. Cirrhosis reduces the ability of synthesizing vitamin K-dependent clotting factors \[[@B34]\]. But intravenous infusion of vitamin K is not recommended to correct the coagulation abnormalities in cirrhosis with bleeding \[[@B20]\]. Indeed, vitamin K failed to achieve a remarkable benefit in the reduction of INR in cirrhosis patients \[[@B35]\]. Similarly, our study also suggested that intravenous infusion of vitamin K brings no benefit for treating gastrointestinal bleeding in patients with cirrhosis.

Due to the retrospective nature of this study, several limitations should be acknowledged. First, not all patients had Child-Pugh and MELD scores due to missing laboratory data. But we conducted the subgroup analyses according to the Child-Pugh class and MELD score. Second, not all patients underwent endoscopy to determine the presence and severity of gastroesophageal varices. But we conducted the subgroup analysis according to the use of endoscopic variceal therapy. Third, different hemostatic drugs during hospitalization were often combined. Fourth, a decision on the use of hemostatic drugs was arbitrarily made by our physicians. But we attempted to conduct the PSM analysis by adjusting 15 confounding factors that are associated with patients\' outcomes. Finally, some hemostatic drugs were domestic, such as ethylenediamine diacetoacetic. Other hemostatic drugs were traditional Chinese medicine, such as Yunnan Baiyao. Both of them were not available in the West. The new topical hemostatic powder represents a user-friendly and effective tool in the management of upper gastrointestinal bleeding during endoscopic therapy procedures \[[@B36]\]. However, it has not been available at our hospital.

In conclusion, the effect of hemostatic drugs on AUGIB in cirrhotic patients was unsatisfactory, because the use of hemostatic drugs did not decrease the 5-day rebleeding rate or the in-hospital mortality in cirrhotic patients with AUGIB. Notably, most of the rebleeding events occurred after the initial use of hemostatic drugs. Recent advances in the management of AUGIB should be acknowledged. Future studies should employ more recent data to validate our findings. Additionally, considering the limitations of our study, well-designed randomized controlled trials are still needed in future.

We are indebted to our study team for establishing and updating our retrospective database, including Junna Dai, Cuihong Zhu, Yun Li, Ying Peng, Zheng Ning, Feifei Hou, Jiancheng, Zhao, Han Deng, Ran Wang, Jing Li, Xintong Zhang, Dan Han, Tingxue Song, Zhong Peng, Wenchun Bao, Yingying Li, Zhaohui Bai, Yang An, and Yanyan Wu of whom all had worked for our study group.
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###### 

Overall analysis of the difference between hemostatic drugs and no hemostatic drugs group.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                              No. Pts   Overall                                  No. Pts   Hemostatic drug group    No. Pts   No hemostatic drug group   *P* value
  -------------------------------------- --------- ---------------------------------------- --------- ------------------------ --------- -------------------------- -----------
  Age (years)                            982       56.01 (6.28-95.13)\                      870       56.01 (6.28-95.13)\      112       55.45 (24.92-84.77)\       0.536
                                                   56.45 ± 11.87                                      56.51 ± 11.76                      56.04 ± 12.76              

  Sex (male) (%)                         982       688 (70.10%)                             870       608 (69.90%)             112       80 (71.40%)                0.737

  Cancer (%)                             982       189 (19.20%)                             870       169 (19.40%)             112       20 (17.90%)                0.692

   Liver cancer (%)                      982       160 (16.30%)                             870       142 (16.30%)             112       18 (16.10%)                0.946

   Extrahepatic cancer (%)               982       29 (3.00%)                               870       27 (3.10%)               112       2 (1.80%)                  0.438

  Clinical features of AUGIB (%)                                                                                                                                    

   Hematemesis (%)                       982       587 (59.80%)                             870       541 (62.20%)             112       46 (41.10%)                \<0.001

   Melena (%)                            982       770 (78.40%)                             870       675 (77.60%)             112       95 (84.80%)                0.080

   Hematemesis and melena (%)            982       375 (38.20%)                             870       346 (39.80%)             112       29 (25.90%)                0.004

  Etiology of liver diseases             982                                                870                                112                                  0.305

   HBV (%)                               982       399 (40.60%)                             870       359 (41.30%)             112       40 (35.70%)                0.260

   HCV (%)                               982       83 (8.50%)                               870       75 (8.60%)               112       8 (7.10%)                  0.597

   Alcohol abuse (%)                     982       354 (36.00%)                             870       315 (36.20%)             112       39 (34.80%)                0.774

   HBV+alcohol abuse (%)                 982       106 (10.80%)                             870       94 (10.80%)              112       12 (10.70%)                0.977

   HCV+alcohol abuse (%)                 982       18 (1.80%)                               870       14 (1.60%)               112       4 (3.60%)                  0.145

   Other or unknown etiology (%)         982       186 (18.90%)                             870       159 (18.30%)             112       27 (24.10%)                0.138

  Endoscopic evaluation of EV (%)        982       563 (57.30%)                             870       503 (57.80%)             112       60 (53.60%)                0.393

   No EV (%)                             982       34 (3.50%)                               870       26 (3.00%)               112       8 (7.10%)                  0.024

   Mild EV (%)                           982       27 (2.70%)                               870       26 (3.00%)               112       1 (0.90%)                  0.202

   Moderate EV (%)                       982       66 (6.70%)                               870       60 (6.90%)               112       6 (5.40%)                  0.540

   Severe EV (%)                         982       437 (44.50%)                             870       392 (45.10%)             112       45 (40.20%)                0.328

  Laboratory tests                                                                                                                                                  

   Red Blood Cell (10^12^/L)             973       2.54 (0.79-5.94)\                        864       2.52 (0.79-5.49)\        109       2.81 (1.21-5.08)\          0.002
                                                   2.62 ± 0.70                                        2.59 ± 0.69                        2.81 ± 0.71                

   Hemoglobin (g/L)                      974       72.00 (19.00-180.00)\                    865       72.00 (19.00-180.00)\    109       75.00 (31.00-170.00)\      0.165
                                                   75.10 ± 22.58                                      74.75 ± 22.47                      77.88 ± 23.38              

   White blood cell (10^9^/L)            974       4.90 (0.80-46.10)\                       865       4.90 (0.80-46.10)\       109       4.50 (1.10-30.70)\         0.658
                                                   6.17 ± 4.75                                        6.19 ± 4.76                        6.02 ± 4.69                

   Platelet (10^9^/L)                    974       76.00 (9.00-842.00)\                     865       75.00 (9.00-775.00)\     109       84.00 (17.00-842.00)\      0.010
                                                   95.96 ± 77.81                                      93.75 ± 74.28                      113.51 ± 100.29            

   Total bilirubin (*μ*mol/L)            964       20.70 (3.30-553.60)\                     855       20.60 (3.30-553.60)\     109       22.60 (5.90-241.40)\       0.857
                                                   31.34 ± 39.68                                      31.38 ± 40.46                      31.04 ± 33.14              

   Albumin (g/L)                         949       29.90 (9.60-49.30)\                      841       29.60 (9.60-49.30)\      108       31.45 (13.60-48.40)\       0.002
                                                   29.69 ± 6.75                                       29.43 ± 6.69                       31.66 ± 6.94               

   Alanine aminotransferase (U/L)        962       24.00 (5.00-1064.00)\                    853       24.00 (5.00-1064.00)\    109       24.00 (5.00-438.00)\       0.764
                                                   37.64 ± 61.52                                      37.66 ± 62.94                      37.40 ± 49.23              

   Aspartate aminotransferase (U/L)      962       32.00 (7.00-1487.00)\                    853       32.00 (7.00-1487.00)\    109       31.00 (13.00-994.00)\      0.906
                                                   58.93 ± 117.01                                     58.87 ± 117.48                     59.39 ± 113.76             

   Alkaline phosphatase (U/L)            962       74.90 (1.30-889.00)\                     853       73.00 (1.30-889.00)\     109       84.00 (28.00-868.00)\      0.002
                                                   99.86 ± 88.33                                      97.68 ± 85.57                      116.92 ± 106.48            

   Gamma-glutamyl transpeptidase (U/L)   962       40.00 (5.00-1168.00)\                    853       39.00 (5.00-1168.00)\    109       48.00 (10.00-994.00)\      0.126
                                                   87.40 ± 126.42                                     83.96 ± 119.53                     114.36 ± 169.35            

   Blood urea nitrogen (mmol/L)          932       7.81 (1.54-55.01)\                       827       7.94 (1.54-49.19)\       105       6.19 (2.22-55.01)\         \<0.001
                                                   9.12 ± 5.99                                        9.28 ± 5.85                        7.92 ± 6.90                

   Serum creatinine (*μ*mol/L)           930       60.20 (20.00-1189.00)\                   825       61.00 (20.00-1189.00)\   105       57.00 (28.00-919.00)\      0.154
                                                   72.69 ± 69.59                                      72.43 ± 66.07                      74.77 ± 93.11              

   Potassium (mmol/L)                    952       4.07 (2.13-7.87)\                        845       4.09 (2.13-7.87)\        107       4.00 (2.79-5.80)\          0.003
                                                   4.11 ± 0.55                                        4.13 ± 0.57                        4.00 ± 0.43                

   Sodium (mmol/L)                       952       138.60 (83.00-160.80)\                   845       138.70 (83.00-160.10)\   107       138.00 (118.70-160.80)\    0.146
                                                   138.17 ± 5.14                                      138.22 ± 5.14                      137.84 ± 5.21              

   Prothrombin time (seconds)            922       16.20 (10.80-62.80)\                     816       16.30 (11.00-62.80)\     106       14.95 (10.80-40.90)\       \<0.001
                                                   17.29 ± 4.82                                       17.44 ± 4.89                       16.13 ± 4.17               

   INR                                   920       1.31 (0.77-7.96)\                        814       1.33 (0.79-7.96)\        106       1.18 (0.77-4.19)\          \<0.001
                                                   1.45 ± 0.58                                        1.46 ± 0.59                        1.32 ± 0.48                

  Child-Pugh score                       901       7.00 (5.00-15.00)\                       798       7.00 (5.00-15.00)\       103       7.00 (5.00-14.00)\         0.187
                                                   7.78 ± 2.00                                        7.81 ± 1.95                        7.51 ± 2.30                

  Child-Pugh class A/B/C (%)             901       256 (28.40%)/476 (52.80%)/169 (18.80%)   798       215 (26.90%)/433\        103       41 (39.80%)/43\            0.018
                                                                                                      (54.30%)/150 (18.80%)              (41.70%)/19 (18.40%)       

  MELD score                             895       6.60 (-7.52-40.95)\                      795       6.74 (-7.44-39.17)\      100       5.21 (-7.52-40.95)\        0.056
                                                   7.59 ± 6.71                                        7.76 ± 6.64                        6.24 ± 7.09                

  Vasoactive drugs (%)                   982       892 (90.80%)                             870       815 (93.70%)             112       77 (68.80%)                \<0.001

   Somatostatin (%)                      982       814 (82.90%)                             870       755 (86.80%)             112       59 (50.40%)                \<0.001

   Octreotide (%)                        982       379 (38.60%)                             870       332 (38.20%)             112       47 (42.00%)                0.436

  Proton-pump inhibitors (%)             982       967 (98.50%)                             870       864 (99.30%)             112       103 (92.00%)               \<0.001

  Red blood cell transfusion (%)         982       611 (62.20%)                             870       561 (64.50%)             112       50 (44.60%)                \<0.001

  Antibiotics (%)                        982       468 (47.70%)                             870       416 (47.80%)             112       52 (46.40%)                0.782

  5-day rebleeding (%)                   981       163 (16.60%)                             869       157 (18.10%)             112       6 (5.40%)                  0.001

  In-hospital death (%)                  982       67 (6.80%)                               870       62 (7.10%)               112       5 (4.50%)                  0.293
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: Pts: patients; HBV: hepatitis B virus; HCV: hepatitis C virus; AUGIB: acute upper gastrointestinal bleeding; INR: international normalized ratio; APTT: activated partial thromboplastin time; MELD: model for end-stage liver disease; EV: esophageal varices.

###### 

PSM analysis of difference between hemostatic drugs and no hemostatic drug groups.

  ---------------------------------------------------------------------------------------------------------------------------
  Variables                              No. Pts   Hemostatic drugs group    No. Pts   No hemostatic drug group   *P* value
  -------------------------------------- --------- ------------------------- --------- -------------------------- -----------
  Age (years)                            86        55.60 (30.37-89.23)\      86        55.78 (24.92-84.77)\       0.504
                                                   57.00 ± 11.39                       55.65 ± 11.73              

  Sex (male) (%)                         86        60 (69.80%)               86        62 (72.10%)                0.737

  Cancer (%)                             86        10 (11.60%)               86        16 (18.60%)                0.201

   Liver cancer (%)                      86        8 (9.30%)                 86        15 (17.40%)                0.117

   Extrahepatic cancer (%)               86        2 (2.30%)                 86        1 (1.20%)                  0.560

  Clinical features of AUGIB (%)                                                                                  

   Hematemesis (%)                       86        33 (38.40%)               86        36 (41.90%)                0.641

   Melena (%)                            86        72 (83.70%)               86        74 (86.00%)                0.670

   Both hematemesis and melena (%)       86        19 (22.10%)               86        24 (27.90%)                0.379

  Etiology of liver diseases                                                                                      

   HBV (%)                               86        22 (25.60%)               86        32 (37.20%)                0.100

   HCV (%)                               86        5 (5.80%)                 86        7 (8.10%)                  0.549

   Alcohol abuse (%)                     86        33 (38.40%)               86        34 (39.50%)                0.876

   HBV+alcohol abuse (%)                 86        6 (7.00%)                 86        11 (12.80%)                0.201

   HCV+alcohol abuse (%)                 86        3 (3.50%)                 86        4 (4.70%)                  0.700

   Other or unknown etiology (%)         86        35 (40.70%)               86        29 (33.70%)                0.344

  Endoscopic evaluation of EV (%)        86        53 (61.60%)               86        49 (57.00%)                0.535

   No EV (%)                             86        5 (5.80%)                 86        7 (8.10%)                  0.549

   Mild EV (%)                           86        3 (3.50%)                 86        1 (1.20%)                  0.312

   Moderate EV (%)                       86        6 (7.00%)                 86        5 (5.80%)                  0.755

   Severe EV (%)                         86        39 (45.30%)               86        36 (41.90%)                0.646

  Laboratory tests                                                                                                

   Red Blood Cell (10^12^/L)             86        2.58 (0.93-5.07)\         86        2.68 (1.21-4.22)\          0.438
                                                   2.67 ± 0.73                         2.71 ± 0.62                

   Hemoglobin (g/L)                      86        73.00 (31.00-157.00)\     86        73.50 (42.00-122.00)\      0.608
                                                   78.64 ± 24.96                       74.99 ± 19.85              

   White blood cell (10^9^/L)            86        4.05 (1.00-25.20)\        86        4.20 (1.10-30.70)\         0.400
                                                   5.35 ± 4.29                         5.70 ± 4.62                

   Platelet (10^9^/L)                    86        70.50 (9.00-775.00)\      86        82.00 (17.00-842.00)\      0.103
                                                   97.90 ± 96.51                       111.50 ± 105.11            

   Total bilirubin (*μ*mol/L)            86        20.10 (4.80-553.60)\      86        23.25 (5.90-241.40)\       0.968
                                                   35.42 ± 64.87                       30.03 ± 30.64              

   Albumin (g/L)                         85        30.90 (17.20-49.30)\      85        31.20 (13.60-48.00)\       0.337
                                                   30.60 ± 6.47                        31.58 ± 7.12               

   Alanine aminotransferase (U/L)        86        26.00 (6.00-184.00)\      86        23.00 (5.00-438.00)\       0.548
                                                   32.23 ± 24.92                       37.58 ± 53.46              

   Aspartate aminotransferase (U/L)      86        35.50 (8.00-228.00)\      86        30.50 (13.00-994.00)\      0.218
                                                   49.35 ± 42.70                       60.43 ± 125.71             

   Alkaline phosphatase (U/L)            86        76.30 (36.00-707.00)\     86        92.50 (28.00-450.00)\      0.381
                                                   114.00 ± 102.19                     104.13 ± 61.66             

   Gamma-glutamyl transpeptidase (U/L)   86        55.50 (8.00-1168.00)\     86        49.50 (10.00-994.00)\      0.454
                                                   131.82 ± 209.08                     103.97 ± 154.16            

   Blood urea nitrogen (mmol/L)          86        7.37 (2.07-24.92)\        86        6.20 (2.22-55.01)\         0.177
                                                   8.54 ± 4.91                         8.04 ± 7.18                

   Serum Creatinine (*μ*mol/L)           86        55.00 (24.00-449.00)\     86        57.00 (28.00-919.00)\      0.565
                                                   65.36 ± 49.07                       72.37 ± 97.01              

   Potassium (mmol/L)                    85        4.07 (2.13-5.48)\         85        4.00 (2.79-5.80)\          0.430
                                                   4.08 ± 0.55                         4.02 ± 0.45                

   Sodium (mmol/L)                       85        139.40 (128.90-147.30)\   85        137.60 (122.60-146.50)\    0.023
                                                   139.08 ± 3.77                       137.51 ± 4.47              

   Prothrombin time (seconds)            86        15.60 (12.90-47.00)\      86        15.25 (10.80-40.90)\       0.280
                                                   16.71 ± 4.44                        16.37 ± 4.44               

   INR                                   86        1.25 (0.97-5.21)\         86        1.20 (0.77-4.19)\          0.219
                                                   1.38 ± 0.53                         1.34 ± 0.51                

  Child-Pugh score                       86        7.00 (5.00-14.00)\        86        7.00 (5.00-14.00)\         0.460
                                                   7.63 ± 2.05                         7.52 ± 2.33                

  Child-Pugh class A/B/C (%)             86        29 (33.70%)/42\           86        35 (40.70%)/35\            0.585
                                                   (48.80%)/15 (17.50%)                (40.70%)/16 (18.60%)       

  MELD score                             86        5.27 (-6.44-32.06)\       86        5.09 (-7.52-40.95)\        0.861
                                                   6.28 ± 6.84                         6.17 ± 7.05                

  Endoscopic variceal treatment (%)      86        45 (52.30%)               86        38 (44.20%)                0.285

  Vasoactive drugs (%)                   86        67 (77.90%)               86        65 (75.60%)                0.718

   Somatostatin (%)                      86        60 (69.80%)               86        49 (57.70%)                0.082

   Octreotide (%)                        86        31 (36.00%)               86        40 (46.50%)                0.163

  Proton-pump inhibitors (%)             86        83 (96.50%)               86        84 (97.70%)                0.650

  Antibiotics (%)                        86        41 (47.70%)               86        43 (50.00%)                0.760

  Red blood cell transfusion (%)         86        47 (54.70%)               86        44 (51.20%)                0.647

  5-day rebleeding (%)                   86        13 (15.10%)               86        5 (5.80%)                  0.046

  In-hospital death (%)                  86        6 (7.00%)                 86        3 (3.50%)                  0.304
  ---------------------------------------------------------------------------------------------------------------------------

Abbreviations: Pts: patients; HBV: hepatitis B virus; HCV: hepatitis C virus; AUGIB: acute upper gastrointestinal bleeding; INR: international normalized ratio; APTT: activated partial thromboplastin time; MELD: model for end-stage liver disease; EV: esophageal varices.
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